News & Updates

Treatment with the combination of pitavastatin plus ezetimibe effectively lowers low-density lipoprotein cholesterol (LDL-C) levels by more than 50 percent, with a safety profile comparable to that of pitavastatin monotherapy, according to the results of a phase III study.

Starting alirocumab early in the hospital prior to undergoing percutaneous coronary intervention (PCI) reduces LDL-cholesterol (LDL-C) in STEMI* patients already on high-statin therapy.

Preoperative administration of gabapentin helps reduce intraoperative pain in women undergoing second-trimester surgical abortion, leading to improved satisfaction with pain management, as shown in a randomized, controlled, double-blind trial.

Prophylactic treatment with trimethoprim (TMP)-sulfamethoxazole (SMX) at a low dose helps lower the risk of Pneumocystis jirovecii pneumonia (PJP) within 6 months following kidney transplantation, according to a study.

Adjuvant chemotherapy with a modified dose of FOLFIRINOX (mFOLFIRINOX) was associated with significantly better survival outcomes, particularly disease-free survival (DFS) and overall survival (OS), compared with single-agent gemcitabine in patients with resected pancreatic ductal adenocarcinoma (PDAC), according to a 5-year analysis of the PRODIGE 24/Canadian Cancer Trials Group PA6* study.

New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.